Navigation Links
Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol
Date:11/19/2013

ns and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.

CONTACT: Amgen
Ashleigh Koss: 805-313-6151 (media)
Arvind Sood: 805-447-1060 (investors)

'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
2. Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
3. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
4. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
5. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
6. Amgen And Servier Complete Product Collaboration Transaction
7. Amgen Announces 2013 Third Quarter Dividend
8. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
9. Amgen And Servier Announce Product Collaboration
10. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
11. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... (PRWEB) April 17, 2015 BellBrook ... and marketing support for the powerful Orthogonal Pooled ... Chemical Genomics Center at the Lankenau Institute for ... mission is to measurably improve successful drug discovery ... by offering rare, drug-like libraries available nowhere else, ...
(Date:4/16/2015)... South San Francisco, CA (PRWEB) April 16, 2015 ... it is scheduled to report first quarter results on ... Following the announcement, Cytokinetics’ senior management will host a ... operational and financial results and the company’s outlook for ... webcast and can be accessed from the homepage and ...
(Date:4/16/2015)... Regis Technologies looks forward to being part ... (AACR) annual meeting. Regis will exhibit at this year's ... 18, in Philadelphia and running through April 22, 2015. ... oldest and largest organization focused on cancer research. It ... with survivors to promote awareness and research funding. ...
(Date:4/16/2015)... , April 16, 2015  In recognition of World ... with hemophilia advocacy groups to illuminate more than 15 prominent ... including Boston,s Zakim Bridge and Prudential ... New Orleans, Mercedes-Benz Superdome and Denver,s ... during the evening of April 17, and coincide with hemophilia ...
Breaking Biology Technology:BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4
... 11 Oxford Genome Sciences (UK),Ltd "OGeS" announces ... Board (SAB) with the appointment of Sir Walter ... in the Weatherall,Institute of Molecular Medicine at the ... genetic and biological changes which,lead to the development ...
... Conference Call Scheduled for 8:30 a.m. ET, FULLERTON, ... ) announced today it will host a conference call ... discuss the company,s third quarter,results. Earnings will be released ... The call may be accessed by dialing (877) 516-3365 ...
... The National,Institutes of Allergy and Infectious Diseases ... Nordic to include the initiation of,a larger Phase ... in persons diagnosed with atopic dermatitis. The contract,extension ... has a value of,US$15 million, with the majority ...
Cached Biology Technology:Sir Walter Bodmer Joins Oxford Genome Sciences Scientific Advisory Board 2Sir Walter Bodmer Joins Oxford Genome Sciences Scientific Advisory Board 3Beckman Coulter Announces Third Quarter 2007 Earnings to Be Released on Tuesday, October 30, 2007 Before Market Opens 2Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema 2Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema 3
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... power our homes and offices is an unaccomplished dream due ... solar energy. The study of photosynthesis in plants could provide ... the sun-light reaching them, and how they transform it into ... Dau, from the Freie Universität Berlin, used the X-ray source ...
... Bacterial leaf scorch is severely affecting urban shade trees ... clear the air, reduce noise, and improve the aesthetics ... American Phytopathological Society (APS). , According to ... New Brunswick, NJ, bacterial leaf scorch (BLS) affects many ...
... have developed a customized gene chip to rapidly scan ... to prognosis in cases of neuroblastoma, a common form ... the microarray focuses on suspect regions of chromosomes for ... role in the cancer. , The investigators, from The ...
Cached Biology News:Plants reveal a secret and bring researchers nearer a cleaner future 2Shade trees getting 'scorched' by plant disease 2Customized gene chip provides rapid detection of genetic changes in children's cancer 2Customized gene chip provides rapid detection of genetic changes in children's cancer 3
... Genome ChIP-on-chip Microarray is specifically designed ... cerevisiae) DNA binding proteins by pairing ... microarrays. This set delivers robust hybridization ... true binding events and fewer false ...
... Dithiothreitol DTT ... INERT GAS. Purity: ≥99% ... metals: Absorbance: (100 ... Soluble in EtOH or H ...
... Whole Genome ChIP-on-chip Microarray is specifically ... (S. pombe) DNA binding proteins by ... DNA microarrays. This set delivers robust ... greater true binding events and fewer ...
... sequencing of Salmonella genomes has allowed the ... PCR* primer pairs. The S. enterica Typhimurium ... chromosome (4,857,432 bp; 4,440 ORFs) and a ... ORFmers from Sigma-Genosys have been designed to ...
Biology Products: